Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $12.4M | $8.78M | $36.6M | $184M |
| Revenue growth | — | — | — | — | — | -29.2% | 316.3% | 404.5% |
| Operating income | -$12.8M | -$35.7M | -$53.0M | -$86.1M | -$104M | -$115M | -$101M | -$20.6M |
| Operating margin | — | — | — | — | -841.2% | -1307.2% | -277.3% | -11.2% |
| Net income | -$12.5M | -$32.3M | -$52.2M | -$85.8M | -$101M | -$105M | -$89.0M | -$6.88M |
| Net margin | — | — | — | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| EPS (diluted) | -$17.65 | -$1.80 | -$1.56 | -$2.34 | -$2.60 | -$2.38 | -$1.65 | -$0.12 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$31.1M | -$42.2M | -$66.9M | -$31.9M | -$81.1M | -$86.9M | $45.6M |
| Capital expenditures | $935K | $1.64M | $1.05M | $1.20M | $3.96M | $1.62M | $203K | $670K |
| Free cash flow | -$11.9M | -$32.7M | -$43.3M | -$68.1M | -$35.8M | -$82.7M | -$87.1M | $44.9M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $105M | $222M | $287M | $145M | $114M | $191M | $128M | $84.2M |
| Total assets | $108M | $229M | $298M | $239M | $256M | $228M | $272M | $418M |
| Total liabilities | $2.47M | $4.32M | $11.8M | $21.1M | $71.2M | $68.8M | $42.5M | $66.0M |
| Shareholders' equity | $105M | $224M | $286M | $218M | $185M | $160M | $229M | $352M |
| Retained earnings | -$25.7M | -$58.0M | -$110M | -$196M | -$297M | -$402M | -$491M | -$498M |
| Shares (wtd avg diluted) | 727K | 32.9M | 36.6M | 36.7M | 38.9M | 44.0M | 54.0M | 59.2M |
Every figure is extracted from Stoke Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.